研究：混打AZ、BNT疫苗，應注意較強烈的不良反應與接種順序

[2] Barros-Martins, Joana, et al. "Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination." Nature medicine 27.9 (2021): 1525-1529.

[3] Hammerschmidt, S.I., Bosnjak, B., Bernhardt, G. et al. (2021) "Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination." Cell Mol Immunol 18, 2455–2456. https://doi.org/10.1038/s41423-021-00755-z

[4] Shaw, Robert H., et al. "Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data." The Lancet 397.10289 (2021): 2043-2046.

[5] Liu, Xinxue, et al. (2021) "Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial." The Lancet, 398(10303), 856-869.

[6] Pozzetto, B., Legros, V., Djebali, S. et al. "Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination" Nature (2021).

[7] Chiu, N. C., Chi, H., Tu, Y. K., Huang, Y. N., Tai, Y. L., Weng, S. L., Chang, L., Huang, D. T., Huang, F. Y., & Lin, C. Y. (2021). "To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination." Expert review of vaccines, 20(10), 1211–1220. https://doi.org/10.1080/14760584.2021.1971522

本文經台灣科技媒體中心授權刊登，原文刊載於此

延伸閱讀

• 研究：癌症患者打完兩劑疫苗後免疫力沒有一般人好，未來若有追加劑量應優先接種
• mRNA疫苗造成心肌炎？專家：和染疫後住院相比仍利大於弊
• 最新研究：混打AZ與BNT疫苗，比起施打兩劑BNT疫苗預防COVID-19效果更好

責任編輯：蕭汎如
核稿編輯：翁世航